Bebenek Marek, Duś Danuta, Koźlak Joanna
First Deptartment of Surgical Oncology, Regional Comprehensive Cancer Center, 53-413 Wroclaw, Poland.
Anticancer Res. 2007 Jan-Feb;27(1A):215-8.
Bones belong to the most frequent localizations of breast cancer metastases. Several studies on female breast malignancies have indicated that Fas/Fas-ligand status may have a significant impact on survival. Hence, the aim of our study was to determine if these molecules might serve as the predictors of skeletal dissemination in radically-treated breast cancer patients.
Tumor samples from 147 radically-treated breast cancer patients were studied immunohistochemically for Fas/Fas-ligand expression.
Both Fas and Fas-ligand expression in the primary tumor were considerably less frequent among breast cancer patients with bone metastases compared to women without skeletal spread. Moreover, negative staining for Fas or the lack of Fas-ligand expression proved to be significant predictors for the survival free from bone metastases under univariate analysis.
Our results suggest that the probability of bone metastases may be assessed on the basis of Fas/Fas-ligand expression in primary breast cancer. Consequently, their determination seems crucial for further prognosis and determination of adjuvant treatment.
骨骼是乳腺癌转移最常见的部位之一。多项针对女性乳腺恶性肿瘤的研究表明，Fas/Fas配体状态可能对生存率有重大影响。因此，我们研究的目的是确定这些分子是否可作为根治性治疗的乳腺癌患者骨骼转移的预测指标。
对147例接受根治性治疗的乳腺癌患者的肿瘤样本进行免疫组织化学研究，以检测Fas/Fas配体的表达。
与无骨骼转移的女性相比，发生骨转移的乳腺癌患者原发肿瘤中Fas和Fas配体的表达频率明显较低。此外，在单因素分析中，Fas染色阴性或缺乏Fas配体表达被证明是无骨转移生存的重要预测指标。
我们的结果表明，可根据原发性乳腺癌中Fas/Fas配体的表达来评估骨转移的可能性。因此，它们的测定对于进一步的预后评估和辅助治疗的确定似乎至关重要。
